Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Epi-Off Clear all
Completed Phase 2 Interventional Results available

Ketoconazole and Dexamethasone in Prostate Cancer

NCT01036594
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ketoconazole, Hydrocortisone, Dexamethasone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 19, 2026, 2:55 AM EDT
Recruiting Not applicable Interventional

TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.

NCT06369922
View directory record Official record
Conditions
Stress Incontinence Female, Urinary Incontinence, Urinary Incontinence,Stress, Pain, Pain Acute
Interventions
TENS, Control TENS
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

NCT00624650
View directory record Official record
Conditions
Acute Lung Injury
Interventions
Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
Drug · Other · Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Clackamas, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 19, 2026, 2:55 AM EDT
Terminated Phase 4 Interventional

Steroid Sensitive Nephrotic Syndrome in Children

NCT03878914
View directory record Official record
Conditions
Nephrotic Syndrome in Children
Interventions
Corticosteroids
Drug
Lead sponsor
Wayne State University
Other
Eligibility
1 Year to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 19, 2026, 2:55 AM EDT
Recruiting Phase 2 Interventional

Belatacept in De Novo Heart Transplantation

NCT04477629
View directory record Official record
Conditions
Heart Transplantation
Interventions
Belatacept, Tacrolimus, Mycophenolate Mofetil, Corticosteroid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 19, 2026, 2:55 AM EDT
Completed No phase listed Observational

Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy

NCT01209507
View directory record Official record
Conditions
Adrenal Suppression
Interventions
Chemotherapy
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 19, 2026, 2:55 AM EDT
Completed No phase listed Observational

Robotic-assisted Laparoscopic Sacrocolpopexy

NCT00581334
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Robotic-assisted laparoscopic sacrocolpopexy, Open sacrocolpopexy
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 19, 2026, 2:55 AM EDT
Not listed Phase 3 Interventional

Corneal Cross-Linking Comparing Variables

NCT02095730
View directory record Official record
Conditions
Unstable Corneas
Interventions
Epithelium-On Riboflavin, Epithelium-Off Riboflavin, UV Light - Continuous Beam, UV Pulsed Beam
Drug · Device
Lead sponsor
Crowd Health Research, LTD
Other
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
16
States / cities
Santa Rosa, California • Denver, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessing the Effect of a Blood-based Colorectal Cancer Screening Test on Screening Adherence and Colonoscopy Completion

NCT03598166
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Septin9
Diagnostic Test
Lead sponsor
Peter S. Liang, MD MPH
Federal
Eligibility
50 Years to 75 Years
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 19, 2026, 2:55 AM EDT
Active, not recruiting Phase 1 Interventional

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

NCT03959891
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Fulvestrant, Aromatase Inhibitor, Palbociclib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 2:55 AM EDT
Enrolling by invitation Phase 2 Interventional

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

NCT03292861
View directory record Official record
Conditions
Heart Transplantation
Interventions
Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 19, 2026, 2:55 AM EDT
Not listed Phase 3 Interventional

Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia

NCT03080077
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Ricrolin+, Epi-Off
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
10 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 19, 2026, 2:55 AM EDT
Terminated Phase 1 Interventional

Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears

NCT01688362
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Platelet Rich Plasma (PRP), Corticosteroid
Biological · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 19, 2026, 2:55 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

NCT02802514
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 19, 2026, 2:55 AM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 2:55 AM EDT
Withdrawn No phase listed Observational

Role of Chemokine and Chemokine Receptor in Psoriasis

NCT03302390
View directory record Official record
Conditions
Psoriasis
Interventions
Shave Biopsy of Psoriasis Lesion
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 19, 2026, 2:55 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 19, 2026, 2:55 AM EDT
Not listed Phase 3 Interventional

The Effects of Corneal Collagen Cross-linking

NCT01708538
View directory record Official record
Conditions
Corneal Ectasia Disorders Including Keratoconus
Interventions
CXL
Drug
Lead sponsor
Rush Eye Associates
Other
Eligibility
10 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

NCT01680861
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids
Drug
Lead sponsor
Gaetano Ciancio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 19, 2026, 2:55 AM EDT
Not listed Phase 3 Interventional

Corneal Collagen Cross-Linking (CXL) Performed With "Epi-ON" Versus "Epi-OFF" in Eyes With Keratoconus and Other Corneal Ectatic Disorders

NCT03858036
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Ricrolin+, VEGA UV-A system
Drug · Device
Lead sponsor
Center for Sight, Sacramento, CA
Other
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 19, 2026, 2:55 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage

NCT03065465
View directory record Official record
Conditions
Upper Gastrointestinal Hemorrhage
Interventions
Over-the-scope hemoclipping device, Standard endoscopic treatment
Device · Other
Lead sponsor
CURE Digestive Diseases Research Center
Other
Eligibility
18 Years to 100 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

NCT00805207
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Obstructive Sleep Apnea, Obesity
Interventions
Progesterone, testosterone, glucocorticoid, continuous positive airway pressure, Estrogen, Control
Drug · Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 19, 2026, 2:55 AM EDT
Recruiting Phase 4 Interventional

Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis

NCT07418593
View directory record Official record
Conditions
Chronic Pancreatitis, Recurrent Acute Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions
Pancreatic Enzyme Replacement Therapy, Placebo, MBT1, MBT 2
Drug · Diagnostic Test
Lead sponsor
Anna Evans Phillips
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

NCT00801632
View directory record Official record
Conditions
Kidney Transplantation, Kidney Failure, Chronic
Interventions
Kidney Transplantation, Bone marrow transplantation, MEDI-507, cyclophosphamide, rituximab, Tacrolimus, corticosteroids, thymic irradiation
Procedure · Biological · Drug + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 19, 2026, 2:55 AM EDT